J
Jeff M. Michalski
Researcher at Washington University in St. Louis
Publications - 393
Citations - 24291
Jeff M. Michalski is an academic researcher from Washington University in St. Louis. The author has contributed to research in topics: Prostate cancer & Radiation therapy. The author has an hindex of 73, co-authored 330 publications receiving 20977 citations. Previous affiliations of Jeff M. Michalski include American Urological Association & American Society for Radiation Oncology.
Papers
More filters
Journal ArticleDOI
Penile bulb dose and impotence after three-dimensional conformal radiotherapy for prostate cancer on RTOG 9406: Findings from a prospective, multi-institutional, phase I/II dose-escalation study
Mack Roach,Kathryn Winter,Jeff M. Michalski,James D. Cox,James A. Purdy,Walter Bosch,Xiao Lin,William S. Shipley +7 more
TL;DR: Dose to the bulb of the penis seems to be associated with the risk of radiation-induced impotence in men treated on Radiation Therapy Oncology Group (RTOG) 9406.
Journal ArticleDOI
Survival Among Men With Clinically Localized Prostate Cancer Treated With Radical Prostatectomy or Radiation Therapy in the Prostate Specific Antigen Era
Adam S. Kibel,Jay P. Ciezki,Eric A. Klein,Chandana A. Reddy,Jessica D. Lubahn,Jennifer Haslag-Minoff,Joseph O. Deasy,Jeff M. Michalski,Dorina Kallogjeri,Jay F. Piccirillo,Danny M. Rabah,Changhong Yu,Michael W. Kattan,Andrew J. Stephenson +13 more
TL;DR: After adjusting for major confounders, radical prostatectomy was associated with a small but statistically significant improvement in overall and cancer specific survival.
Journal ArticleDOI
No clinically significant changes in pulmonary function following stereotactic body radiation therapy for early- stage peripheral non-small cell lung cancer: An analysis of RTOG 0236
Sinisa Stanic,Rebecca Paulus,Robert Timmerman,Jeff M. Michalski,Robert B. Barriger,Andrea Bezjak,Gregory M.M. Videtic,Jeffrey D. Bradley +7 more
TL;DR: Poor baseline PFT did not appear to predict pulmonary toxicity or decreased overall survival after SBRT in this medically inoperable population and should not be used to exclude patients with early stage lung cancer from treatment with S BRT.
Journal ArticleDOI
Improved biochemical relapse-free survival with increased external radiation doses in patients with localized prostate cancer: the combined experience of nine institutions in patients treated in 1994 and 1995
Patrick A. Kupelian,Patrick A. Kupelian,Deborah A. Kuban,Howard D. Thames,Larry B. Levy,Eric M. Horwitz,Alvaro Martinez,Jeff M. Michalski,Thomas M. Pisansky,Howard M. Sandler,William U. Shipley,Michael J. Zelefsky,Anthony L. Zietman +12 more
TL;DR: The radiation dose-response as determined by Kaplan-Meier prostate-specific antigen ( PSA) disease-free survival (PSA-DFS) estimates in patients with stage T1-T2 prostate cancer treated within a 2-year period (1994-1995) was studied.
Journal ArticleDOI
Definitions of biochemical failure that best predict clinical failure in patients with prostate cancer treated with external beam radiation alone: a multi-institutional pooled analysis.
Eric M. Horwitz,Howard D. Thames,Deborah A. Kuban,Larry B. Levy,Patrick A. Kupelian,Alvaro Martinez,Jeff M. Michalski,Thomas M. Pisansky,H.M. Sandler,William U. Shipley,Michael J. Zelefsky,Gerald E. Hanks,Anthony L. Zietman +12 more
TL;DR: Using what is to the authors' knowledge the largest data set of patients with prostate cancer treated with RT alone, multiple definitions of BF with the strict clinical end points of DF alone and CF (DF or local failure) are correlated.